// App-Quantinova.ai

1906 : Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) – Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

Researchers

Presenter

  • William Donnellan

Principal Investigators

  • Tao Xu

  • Esprit Ma

  • Huan Jin

  • Melissa Montez

  • Michelle Choi

  • Grace Ku

  • Raj Anand Rajeswaran

  • Giridharan Ramsingh

  • Evelyn M. Flahavan

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • AbbVie, Inc., North Chicago, IL

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • United States

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT02203773

  • NCT02993523

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved